The study focuses on advanced KRASG12C mutant NSCLC, advanced KRASG12C mutant non-NSCLC, solid tumors with other MAPK pathway mutations, and advanced EGFR-mutant NSCLC [5]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.